Form 4: Ionis CFO's Stock Transactions: PRSU Vesting & Sale

Ionis Pharmaceuticals' EVP, Finance & CFO, Elizabeth L. Hougen, acquired shares from vested performance-based restricted stock units and subsequently sold a portion of her common stock.

Summary

• Elizabeth L. Hougen, EVP, Finance & CFO of Ionis Pharmaceuticals Inc. (IONS), reported changes in her beneficial ownership.
• On January 29, 2026, Ms. Hougen acquired 13,562 shares of common stock at a price of $0.0.
• These shares were earned upon the vesting of performance-based restricted stock units (PRSUs) granted on January 18, 2023.
• The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return compared to a peer group, resulting in a vest of 167.27% of target shares.
• The PRSUs had a potential payout range of 0% to 200% based on actual goal achievement.
• Following this acquisition, Ms. Hougen's beneficial ownership was 139,869 shares.
• On January 30, 2026, Ms. Hougen disposed of 6,988 shares of common stock at a weighted average price of $83.243 per share.
• The shares were sold in multiple transactions with prices ranging from $83.11 to $83.32.
• After the disposition, Ms. Hougen's beneficial ownership stands at 132,881 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to the strong performance indicated by the 167.27% vesting of performance-based restricted stock units, reflecting excellent relative shareholder return. The subsequent sale is a routine insider transaction, which slightly tempers the overall sentiment but does not negate the underlying positive performance.

Positives

• The vesting of performance-based restricted stock units at 167.27% of target shares indicates strong performance by Ionis Pharmaceuticals relative to its peer group in terms of total shareholder return.
• The successful achievement of performance goals for executive compensation aligns management incentives with shareholder value creation.

Negatives

• The sale of 6,988 shares by a key executive, even if routine or for diversification, could be perceived as a slight negative by some investors, though it represents a small portion of her total holdings.

Future Outlook

This Form 4 filing reports past transactions and does not contain any explicit forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 167.27% of target shares.

Industry Context

StockSavvy.ai notes that insider transactions, such as the vesting of performance-based awards and subsequent sales, are common occurrences in publicly traded companies. The high achievement rate of the PRSUs (167.27%) suggests that Ionis Pharmaceuticals has outperformed its peer group in terms of total shareholder return, which is a positive indicator for the company's competitive standing within the biotechnology or pharmaceutical industry.

Comparison to Industry Standards

• The vesting of performance-based restricted stock units at 167.27% of target indicates strong relative performance against a peer group, suggesting Ionis Pharmaceuticals' total shareholder return exceeded the median of its comparable companies. This level of outperformance is generally considered excellent within executive compensation structures tied to relative metrics.

Stakeholder Impact

• Shareholders may view the high vesting percentage of performance-based restricted stock units positively, as it reflects strong company performance and alignment of executive incentives with shareholder value.
• The sale of shares by a key executive is a routine event that may be interpreted differently by various investors, but it is a common practice for diversification or liquidity.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Form 4, Insider Transaction, Elizabeth L. Hougen, CFO, Performance-Based Restricted Stock Units, PRSU, Stock Vesting, Stock Sale, Executive Compensation